Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.09B

Market cap19.09B

Price-Earnings ratio

14.96

Price-Earnings ratio14.96

Dividend yield

—

Dividend yield—

Average volume

1.72M

Average volume1.72M

High today

$96.05

High today$96.05

Low today

$92.55

Low today$92.55

Open price

$93.02

Open price$93.02

Volume

1.16M

Volume1.16M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

With a market cap of 19.09B, Incyte(INCY) trades at $95.04. The stock has a price-to-earnings ratio of 14.96.

On 2026-04-06, Incyte(INCY) stock moved within a range of $92.55 to $96.05. With shares now at $95.04, the stock is trading +2.7% above its intraday low and -1.1% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.16M, versus its average volume of 1.72M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

Simply Wall St 2d

Incyte Is Up 6.2% After Positive 54-Week HS and IO Combo Data - What's Changed

In late March 2026, Incyte reported 54-week Phase 3 STOP-HS data showing durable efficacy and a consistent safety profile for its oral JAK1 inhibitor povorcitin...

TipRanks 4d

Adagene enters pact with Incyte for combination of muzastotug, INCA33890

Adagene (ADAG) announced a clinical collaboration with Incyte (INCY) to evaluate the combination of muzastotug and INCA33890, a TGFbetaR2 PD-1 bispecific antibo...

Simply Wall St 4d

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The...

Analyst ratings

52%

of 29 ratings

Buy

37.9%

Hold

51.7%

Sell

10.3%

More INCY News

Simply Wall St 6d

Assessing Incyte Valuation After Recent Share Price Weakness And Mixed Fair Value Signals

Without a specific news catalyst, Incyte (INCY) has attracted attention after a period where the share price shows a one-month return of about negative 11% and...

TipRanks 6d

Incyte Announces Upcoming Resignation of Board Member Schaffert

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.